Flagship Pioneering, NUS Medicine, NUH and NUHS Collaborate to Advance Biotech Research & Development

Flagship Pioneering, NUS Medicine, NUH, and NUHS announce a collaboration to advance biotech research and development. The goal is to accelerate innovation in human health and sustainability, with a focus on creating, co-developing, and co-resourcing research projects over a five-year horizon. The partnership aims to expand globally connected scientific dialogue and drive breakthroughs that impact patients and the planet.

Title: Flagship Pioneering, NUS Medicine, NUH, and NUHS Collaborate to Advance Biotech Research and Development

Singapore, May 7, 2025 — Flagship Pioneering, the bioplatform innovation company, has announced a collaborative agreement with the Yong Loo Lin School of Medicine, National University of Singapore (NUS Medicine), National University Hospital (NUH), and the National University Health System (NUHS). The partnership aims to accelerate innovation in human health and sustainability, with a focus on creating, co-developing, and co-resourcing research projects over a five-year horizon.

The collaboration, formalized through a Memorandum of Understanding (MOU), will leverage Flagship's extensive ecosystem of over 40 companies, including Foghorn Therapeutics (NASDAQ: FHTX), Moderna (NASDAQ: MRNA), and Sana Biotechnology (NASDAQ: SANA), to drive breakthroughs in biotechnology. This partnership will create career development and mentorship opportunities for scientists and students of NUS Medicine through potential secondments, internships, and participation in the Flagship Fellowship program [1].

Flagship Pioneering will also tap into the clinical data ecosystem of NUH and NUHS to gain new biological insights, test clinical hypotheses, and improve patient outcomes. "Our collaboration with NUS Medicine, NUH, and NUHS will help us realize our goal to expand the global reach and impact of Flagship and its companies," said André Andonian, Chair of Asia Pacific and Strategic Advisor, Flagship Pioneering. "We are pleased to combine Flagship's signature approach to company creation and development with the scientific expertise, data reach, and translational potential of NUS Medicine, NUH, and NUHS" [1].

NUS Medicine and NUH are uniquely positioned to translate groundbreaking biomedical research into real-world clinical solutions. "Through this partnership with Flagship, we aim to drive greater innovation and bridge the gap between discovery and patient care," said Professor Chong Yap Seng, Dean, NUS Medicine, and Deputy Chief Executive (Education & Research), NUHS. "Together, we can shape a future where practice-changing innovations and transformative health solutions can benefit patients, communities, and the world" [1].

The collaboration is part of Flagship's broader strategy to engage with key players across Singapore's biotech ecosystem to advance breakthroughs that impact patients and the planet. This initiative aligns with Flagship's mission to invent and build bioplatform companies with the potential for multiple products that transform human health or sustainability [1].

References:
[1] https://www.prnewswire.com/apac/news-releases/flagship-pioneering-the-national-university-of-singapore-national-university-hospital-and-the-national-university-health-system-announce-collaboration-to-advance-biotech-research-development-302448001.html